{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-049347","form_type":"8-K","ticker":"CTOR","cik":"0001851484","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2026-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.131547+00:00","generated_at":"2026-05-15T02:23:49.835059+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Citius Oncology ships first international LYMPHIR order to Europe via NPPs","bullets":["Initial shipment of LYMPHIR (denileukin diftitox-cxdl) to Europe through regional distribution partner.","Access via Named Patient Programs (NPPs) in local countries; no EMA marketing authorization.","LYMPHIR FDA-approved Aug 2024 for relapsed/refractory CTCL; US commercial launch in Dec 2025.","Company continues US launch with progress on formulary access, payer coverage, and physician engagement.","CEO Leonard Mazur cites commitment to expanding patient access beyond the US."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-049347","json":"https://secwatch.observer/filing/0001213900-26-049347.json","markdown":"https://secwatch.observer/filing/0001213900-26-049347.md","text":"https://secwatch.observer/filing/0001213900-26-049347.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026049347/0001213900-26-049347-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026049347/ea0288202-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T02:23:49.835059+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}